In October 2016, 3SBio became the exclusive distributor of The Licensed Products are Byetta, Bydureon single dose tray, Bydureon dual chamber pen and Bydureon auto-injector, the details of which are set forth in the Exclusive License Agreement. .Byetta (generic name exenatide injection) is an injectable Glucagon-Like Peptide-1 receptor agonist (GLP-1 RA), administered twice daily as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, which is indicated for treatment of patients who have not achieved adequate glycaemic control on metformin, sulphonylureas, or metformin plus sulphonylureas.  

Byetta was co-developed by AstraZeneca and Eli Lilly and Company in 1995 and was approved by the Food and Drug Administration in the US in April 2005. It was approved 5 in Europe and other countries subsequent to its approval in the US and was approved by the China Food and Drug Administration in August 2009.  

Bydureon is an extended-release formulation of exenatide, administered once weekly as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, which is indicated for treatment of patients who have not achieved adequate glycaemic control on metformin, sulphonylureas, thiazolidines, metformin plus sulphonylureas or thiazolidines, or sulphonylureas plus thiazolidines.  

Bydureon has been shown to provide powerful HbA1c reduction of 1.3~1.9%. Bydureon was approved by the Food and Drug Administration in the US in 2012. Bydureon is currently available in 42 countries worldwide, including European Union countries. AstraZeneca submitted manufacturing application for Bydureon in China in May 2016.  

Diabetes is a chronic disease that occurs when the body cannot produce enough insulin or cannot use insulin, and is diagnosed by observing raised levels of glucose in the blood. Diabetes is one of the non-infectious diseases which severely threaten human health in recent days. According to International Diabetes Federation, the number of diabetes patients globally reached 415 million in 2015, among which 75% of the patients are from low and middle income countries. The number of diabetes patients globally is estimated to reach 642 million in 2040. According to Chinese Diabetes Society, the incidence rate of diabetes in China has risen significantly in the recent 30 years. According to World Health Organization, almost 10% of adults in China (which accounts for approximately 110 million people) currently live with diabetes, and China is becoming the country with the largest number of diabetes patients in the world.